Dr Nick Coupe

Dr Nick Coupe
B.Med Sci, MBBS (Hons), FRACP, MRCP, DPhil, Consultant Medical Oncologist

Languages spoken


Expert in

Chemotherapy, targeted therapies and immunotherapies for the treatment of lung cancer and melanoma

Interested in

Immunotherapy for the treatment of lung cancer and melanoma, early and late phase clinical trials, teaching, education supervision for trainees



51.7239071200697, -1.2145938932540707

After completing his medical and oncology training in Sydney, Dr Nick Coupe moved to Oxford to undertake a fellowship in early-phase clinical trials. Here he developed an interest in skin cancer and lung cancer, as well as the development of new medications to treat cancer.

Dr Coupe was awarded a CRUK fellowship and subsequently completed a PhD at the University of Oxford investigating associations between melanoma and the process of tumour-driven new blood vessel formation (angiogenesis). The results of his work have been published. Dr Coupe has been a consultant at the Oxford NHS site since 2019, specialising in melanoma and lung cancer. He has also actively participated in teaching and leads the departmental governance division.

Dr Coupe also maintains a strong link with early-phase clinical trials and has written a protocol for a novel immunotherapy drug that is currently being tested in patients with lung cancer and melanoma for the very first time. The results have been presented at multiple international conferences and Dr Coupe has been interviewed to discuss the results. He has also been involved in maintaining guidelines to manage side effects for immunotherapy that are in use locally as well as in nearby NHS trusts. 


Dr Coupe has considerable experience in chemotherapy, targeted therapies and in particular, immunotherapies for the treatment of lung cancer and melanoma. He engages well with colleagues both within his trust and other sites and involves others where necessary to discuss difficult and challenging cases.


Dr Coupe is actively involved in clinical research, as a principal investigator of a number of clinical trials at the Churchill site. He is interested in finding novel methods to track outcomes in real-time in the hope of finding ways to improve overall service delivery. He has multiple publications (listed below) and is also interested in teaching and trainee supervision.

Career positions

Current position(s)

  • Consultant Medical Oncologist, Oxford


Current position(s)

  • Medical and oncology training, Sydney University
  • Fellowship in early phase clinical trials, Oxford

Professional memberships

  • General Medical Council
  • Royal Australasian College of Physicians
  • Royal College of Physicians



  • Department of Oncology Clinical Research Training Fellow (phD) prize winner, 2017
  • CRUK funded Clinical Training Research Fellowship, 2015
  • Oxfordshire Health Services Research Committee (OHSRC) competitive research grant
  • John Harris Prize, Sydney University
  • Albert Hing Memorial Prize in Gynaecology, Sydney University

Publications & affiliations

  1. Fane M, Ecker B, Kaur A, Marino G, Alicea G, Coupe N, Douglass S, et al. sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clin Cancer Res. 2020 Nov 1;26:5709–19.
  2. Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125(1):99–108.
  3. Manoharan V, Lee S, Chong S, Yap J, Coupe N, Wilson R, et al. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy. Ann Nucl Med. 2017 May;31(4):315–23.
  4. Lloyd-Lavery A, Hodgson T,Coupe N, Bond S, Shah K, Espinosa O, Payne MJ, Middleton MR, Matin RN. Delayed oral toxicity from long-term vemurafenib therapy. Br J Dermatol. 2016 May;174(5):1159-60
  1. Coupe N, Gupta A, Lord SR. Early phase cancer clinical trials: design, ethics and future directions. Br J Hosp Med (Lond). 2015;76(7):409-13
  1. Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, et al. PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Eur J Cancer. 2015;51(3):359-66